Venatorx Pharmaceuticals
Pennsylvania
United States
About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals is a private pharmaceutical company focused on antibiotics and antivirals.
57 articles about Venatorx Pharmaceuticals
-
Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults
8/15/2023
Venatorx Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic for the potential treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis.
-
Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US
8/14/2023
Venatorx Pharmaceuticals today highlights two recent publications that provide important updates on the changing epidemiology of carbapenem-resistant Enterobacterales (CRE) globally and in the United States (US).
-
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman
3/7/2023
Venatorx Pharmaceuticals today announced changes to its Board of Directors.
-
Venatorx Pharmaceuticals Announces Organizational Changes
12/20/2022
Venatorx Pharmaceuticals today announced two organizational changes: the retirement of its Chief Medical Officer, Timothy Henkel, M.D., Ph.D., and the step-down of Vincent Milano from the Board of Directors.
-
Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
10/20/2022
Venatorx Pharmaceuticals today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.
-
Venatorx Pharmaceuticals to Present at IDWeek 2022
10/11/2022
Venatorx Pharmaceuticals today announced six presentations during IDWeek 2022, October 19-23, 2022, in Washington, DC.
-
Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract
10/3/2022
Venatorx Pharmaceuticals today announced the Biomedical Advanced Research and Development Authority has awarded the company a contract to support the development of cefepime-taniborbactam for the treatment of melioidosis.
-
Money on the Move: March 30-April 5
4/6/2022
The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading. -
Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund
4/4/2022
Venatorx Pharmaceuticals, Inc. announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI
3/10/2022
Venatorx Pharmaceuticals announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections, including acute pyelonephritis.
-
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
3/10/2022
Everest Medicines announced that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1, evaluating cefepime-taniborbactam, an investigational new drug, versus meropenem as a potential treatment for hospitalized adult patients with complicated urinary tract infections, including acute pyelonephritis.
-
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
-
Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs
12/2/2021
Venatorx Pharmaceuticals today announced that Scott McConnell, Pharm.D. has joined the Company as Vice President, Medical Affairs.
-
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
11/1/2021
Venatorx Pharmaceuticals announced today that it has entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”)
-
Less private investment and innovation in the development of new antibiotics are impeding efforts to combat drug-resistant infections.
-
Venatorx Pharmaceuticals to Present Data at IDWeek 2021
9/27/2021
Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.
-
Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam
8/17/2021
Venatorx Pharmaceuticals today announced a comprehensive update about cefepime-taniborbactam, the Company’s intravenous beta-lactam / beta-lactamase inhibitor (BL/BLI)
-
Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
7/28/2021
Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial (ClinicalTrials.gov – NCT04243863) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
-
Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science
6/29/2021
Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.